The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Open accessAbstract
Here, we show that the synaptic vesicle protein SV2A is the brain binding site of levetiracetam (LEV), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy. The LEV-binding site is enriched in synaptic vesicles, and photoaffinity labeling of purified synaptic vesicles confirms that it has an apparent molecular mass of ≈90 kDa. Brain membranes and purified synaptic vesicles from mice lacking SV2A do not bind a tritiated LEV derivative, indicating that SV2A is necessary for LEV binding. LEV and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for LEV binding. No binding was observed to the related isoforms SV2B and SV2C. Furthermore, there is a high degree of correlation between binding affinities of a series of LEV derivatives to SV2A in fibroblasts and to the LEV-binding site in brain. Finally, there is a strong correlation between the affinity of a compound for SV2A and its ability to protect against seizures in an audiogenic mouse animal model of epilepsy. These experimental results suggest that SV2A is the binding site of LEV in the brain and that LEV acts by modulating the function of SV2A, supporting previous indications that LEV possesses a mechanism of action distinct from that of other antiepileptic drugs. Further, these results indicate that proteins involved in vesicle exocytosis, and SV2 in particular, are promising targets for the development of new CNS drug therapies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In 2004, Lynch et al. demonstrated that SV2A is the target of antiepileptic drug levetiracetam.
“In 2004, Lynch et al. demonstrated that SV2A is the target of antiepileptic drug levetiracetam”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Huttner, W. Β., SCHIEBLER, W., Greengard, P., & Camilli, P. V. D. (1983) · The Journal of Cell Biology · doi:10.1083/jcb.96.5.1374 · Cited by 1,172 · see citing works
Buckley, K. M., & Kelly, R. B. (1985) · The Journal of Cell Biology · doi:10.1083/jcb.100.4.1284 · Cited by 713 · see citing works
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
Klitgaard, H., Matagne, A., Gobert, J., & Wülfert, E. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00410-5 · Cited by 506 · see citing works
Self-citationMoonlighting proteins: old proteins learning new tricks
Jeffery, C. J. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00167-7 · Cited by 475 · see citing works
Differential expression of synaptic vesicle protein 2 (SV2) isoforms
Bajjalieh, S., Frantz, G., Weimann, J., McConnell, S., & Scheller, R. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05223.1994 · Cited by 440 · see citing works
Self-citationAbnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415 · see citing works
Self-citationSV2A and SV2B Function as Redundant Ca2+ Regulators in Neurotransmitter Release
Janz, R., Goda, Y., Geppert, M., Missler, M., & Südhof, T. C. (1999) · Neuron · doi:10.1016/s0896-6273(00)81046-6 · Cited by 366 · see citing works
Löscher, W., Hönack, D., & Rundfeldt, C. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37251-9 · Cited by 344 · see citing works
Rigo, J., Hans, G. A., Nguyen, L., Rocher, V., Belachew, S. M., Malgrange, B., Leprince, P., Moonen, G., Selak, I., Matagne, A., et al. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704766 · Cited by 335 · see citing works
Self-citationThe synaptic vesicle protein SV2 is a novel type of transmembrane transporter
Feany, M. Β., Lee, S., Edwards, R. H., & Buckley, K. M. (1992) · Cell · doi:10.1016/0092-8674(92)90319-8 · Cited by 260 · see citing works
SV2, a Brain Synaptic Vesicle Protein Homologous to Bacterial Transporters
Bajjalieh, S. M., Peterson, K., Shinghal, R., & Scheller, R. H. (1992) · Science · doi:10.1126/science.1519064 · Cited by 256 · see citing works
Self-citationNoyer, M., Gillard, M. R., Matagne, A., Hénichart, J., & Wülfert, E. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00436-o · Cited by 255 · see citing works
Self-citationSV2 modulates the size of the readily releasable pool of secretory vesicles
Xu, T., & Bajjalieh, S. M. (2001) · Nature Cell Biology · doi:10.1038/35087000 · Cited by 212 · see citing works
Self-citationLevetiracetam: The Preclinical Profile of a New Class of Antiepileptic Drugs?
Klitgaard, H. (2001) · Epilepsia · doi:10.1111/j.1528-1167.2001.00003.x · Cited by 148 · see citing works
Schivell, A. E., Batchelor, R., & Bajjalieh, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.44.27770 · Cited by 145 · see citing works
Self-citationThe Evaluation and Treatment of Seizures
Desforges, J. F., Scheuer, M. L., & Pedley, T. A. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011223232107 · Cited by 137 · see citing works
Evaluation and Treatment of Seizures
(1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241712 · Cited by 128 · see citing works
Margineanu, D. G., & Klitgaard, H. (2000) · Pharmacological Research · doi:10.1006/phrs.2000.0689 · Cited by 127 · see citing works
Levetiracetam: A Novel Antiepileptic Drug
Hovinga, C. A. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.17.1375.34432 · Cited by 119 · see citing works
Control of neurotransmitter release by an internal gel matrix in synaptic vesicles
Reigada, D., Díez‐Pérez, I., Gorostiza, P., Verdaguer, A., de Aranda, I. G., Pineda, O., Vilarrasa, J., Marsal, J., Blasi, J., Aleu, J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336914100 · Cited by 98 · see citing works
Evaluation of anticonvulsant drugs in DBA/2 mice with sound-induced seizures.
Chapman, A. G., Croucher, M. J., & Meldrum, B. S. (1984) · PubMed · Cited by 96 · see citing works
Tong, X., & Patsalos, P. N. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704141 · Cited by 83 · see citing works
Birnstiel, S., Wülfert, E., & Beck, S. G. (1997) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005097 · Cited by 81 · see citing works
Yasuda, H., Fujii, M., Fujisawa, H., Ito, H., & Suzuki, M. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.083032.x · Cited by 70 · see citing works
Phosphorylation of Synaptic Vesicle Protein 2 Modulates Binding to Synaptotagmin
Pyle, R. A., Schivell, A. E., Hidaka, H., & Bajjalieh, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000674200 · Cited by 70 · see citing works
Self-citationBinding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain
Gillard, M. R., Fuks, B., Michel, P., Vertongen, P., Massingham, R., & Chatelain, P. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.032 · Cited by 61 · see citing works
Self-citationFuks, B., Gillard, M. R., Michel, P., Lynch, B. A., Vertongen, P., Leprince, P., Klitgaard, H., & Chatelain, P. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.033 · Cited by 59 · see citing works
Self-citationDesynchronizing effect of levetiracetam on epileptiform responses in rat hippocampal slices
Niespodziany, I., Klitgaard, H., & Margineanu, D. G. (2003) · Neuroreport · doi:10.1097/00001756-200307010-00017 · Cited by 46 · see citing works
Psychiatric Disorders Before and After Surgery for Epilepsy
Inoue, Y., & Mihara, T. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.05404.x · Cited by 35 · see citing works
Nash, E. M., & Sangha, K. S. (2001) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/58.13.1195 · Cited by 27 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Synaptopathies: synaptic dysfunction in neurological disorders – A review from students to students
Lepeta, K., Lourenco, M. V., Schweitzer, B. C., Martino Adami, P. V., Banerjee, P., Catuara‐Solarz, S., de La Fuente Revenga, M., Guillem, A. M., Haidar, M., Ijomone, O. M., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13713 · Cited by 386 · see citing works
Nabulsi, N. B., Mercier, J., Holden, D., Carré, S., Najafzadeh, S., Vandergeten, M.-C., Lin, S.-F., Deo, A., Price, N., Wood, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168179 · Cited by 296 · see citing works
Johannessen Landmark, C. (2008) · CNS Drugs · doi:10.2165/00023210-200822010-00003 · Cited by 316 · see citing works
Onwordi, E. C., Halff, E. F., Whitehurst, T., Mansur, A., Cotel, M.-C., Wells, L., Creeney, H., Bonsall, D., Rogdaki, M., Shatalina, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14122-0 · Cited by 243 · see citing works
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.10.001 · Cited by 243 · see citing works
Finnema, S. J., Nabulsi, N. B., Mercier, J., Lin, S.-F., Chen, M.-K., Matuskey, D., Gallezot, J.-D., Henry, S., Hannestad, J., Huang, Y., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17724947 · Cited by 218 · see citing works
Synaptic vesicle protein 2 enhances release probability at quiescent synapses
Custer, K. L., Austin, N. S., Sullivan, J. M., & Bajjalieh, S. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2699-05.2006 · Cited by 211 · see citing works
Self-citationSynaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184 · see citing works
SV2 Renders Primed Synaptic Vesicles Competent for Ca<sup>2+</sup>-Induced Exocytosis
Chang, W.-P., & Südhof, T. C. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4521-08.2009 · Cited by 176 · see citing works
Klitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13340 · Cited by 168 · see citing works
Self-citationCyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management
Rawat, C., Kukal, S., Dahiya, U. R., & Kukreti, R. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1592-3 · Cited by 162 · see citing works
Cotrafficking of SV2 and synaptotagmin at the synapse
Yao, J., Nowack, A., Kensel-Hammes, P., Gardner, R. G., & Bajjalieh, S. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4781-09.2010 · Cited by 164 · see citing works
Self-citationGillard, M., Chatelain, P., & Fuks, B. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.022 · Cited by 148 · see citing works
Self-citationNaganawa, M., Li, S., Nabulsi, N., Henry, S., Zheng, M.-Q., Pracitto, R., Cai, Z., Gao, H., Kapinos, M., Labaree, D., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.249144 · Cited by 138 · see citing works
SV2 regulates neurotransmitter release via multiple mechanisms
Nowack, A., Yao, J., Custer, K. L., & Bajjalieh, S. M. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00259.2010 · Cited by 138 · see citing works
Self-citationAntiepileptic drugs and pregnancy outcomes
Wlodarczyk, B. J., Palacios, A. M., George, T. M., & Finnell, R. H. (2012) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35438 · Cited by 138 · see citing works
PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., & Huang, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.038 · Cited by 131 · see citing works
Assessment of a white matter reference region for <sup>11</sup> C-UCB-J PET quantification
Rossano, S., Toyonaga, T., Finnema, S. J., Naganawa, M., Lu, Y., Nabulsi, N., Ropchan, J., De Bruyn, S., Otoul, C., Stockis, A., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19879230 · Cited by 126 · see citing works
Levetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131 · see citing works
Synaptic vesicle protein 2A: basic facts and role in synaptic function
Mendoza‐Torreblanca, J. G., Vanoye‐Carlo, A., Phillips‐Farfán, B. V., Carmona‐Aparicio, L., & Gómez‐Lira, G. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12360 · Cited by 124 · see citing works
Synaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123 · see citing works
The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance
Stout, K. A., Dunn, A. R., Hoffman, C., & Miller, G. W. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00351 · Cited by 112 · see citing works
Puzzling Out Synaptic Vesicle 2 Family Members Functions
Bartholome, O., Van den Ackerveken, P., Sánchez Gil, J., de la Brassinne Bonardeaux, O., Leprince, P., Franzen, R., & Rogister, B. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00148 · Cited by 107 · see citing works
Imaging of Synaptic Density in Neurodegenerative Disorders
Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104 · see citing works
Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro
Himmerich, H., Bartsch, S., Hamer, H., Mergl, R., Schönherr, J., Petersein, C., Munzer, A., Kirkby, K. C., Bauer, K., & Sack, U. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.07.026 · Cited by 100 · see citing works
Levetiracetam and brivaracetam: A review of evidence from clinical trials and clinical experience
Steinhoff, B. J., & Staack, A. M. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419873518 · Cited by 99 · see citing works
Evaluation of<sup>18</sup>F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain
Warnock, G. I., Aerts, J., Bahri, M. A., Bretin, F., Lemaire, C., Giacomelli, F., Mievis, F., Mestdagh, N., Buchanan, T., Valade, A., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.136143 · Cited by 85 · see citing works
Finnema, S. J., Toyonaga, T., Detyniecki, K., Chen, M., Dias, M., Wang, Q., Lin, S., Naganawa, M., Gallezot, J., Lu, Y., et al. (2020) · Epilepsia · doi:10.1111/epi.16653 · Cited by 78 · see citing works
Levetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A
Nowack, A., Malarkey, E. B., Yao, J., Bleckert, A., Hill, J., & Bajjalieh, S. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029560 · Cited by 81 · see citing works
Self-citationTokudome, K., Okumura, T., Shimizu, S., Mashimo, T., Takizawa, A., Serikawa, T., Terada, R., Ishihara, S., Kunisawa, N., Sasa, M., et al. (2016) · Scientific Reports · doi:10.1038/srep27420 · Cited by 75 · see citing works
Synaptic vesicle protein 2A as a potential biomarker in synaptopathies
Heurling, K., Ashton, N. J., Leuzy, A., Zimmer, E. R., Blennow, K., Zetterberg, H., Eriksson, J., Lubberink, M., & Schöll, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.02.001 · Cited by 77 · see citing works
[11C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A
Estrada, S., Lubberink, M., Thibblin, A., Sprycha, M., Buchanan, T., Mestdagh, N., Kenda, B., Mercier, J., Provins, L., Gillard, M., et al. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.03.004 · Cited by 71 · see citing works
Imaging Synaptic Density: The Next Holy Grail of Neuroscience?
Serrano, M. E., Kim, E., Petrinovic, M. M., Turkheimer, F., & Cash, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.796129 · Cited by 67 · see citing works
Finnema, S. J., Rossano, S., Naganawa, M., Henry, S., Gao, H., Pracitto, R., Maguire, R. P., Mercier, J., Kervyn, S., Nicolas, J., et al. (2019) · Epilepsia · doi:10.1111/epi.14701 · Cited by 65 · see citing works
Kaempf, N., Kochlamazashvili, G., Puchkov, D., Maritzen, T., Bajjalieh, S. M., Kononenko, N. L., & Haucke, V. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501627112 · Cited by 63 · see citing works
Self-citationLi, S., Cai, Z., Zhang, W., Holden, D., Lin, S.-F., Finnema, S. J., Shirali, A., Ropchan, J., Carre, S., Mercier, J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04357-w · Cited by 59 · see citing works
Li, S., Naganawa, M., Pracitto, R., Najafzadeh, S., Holden, D., Henry, S., Matuskey, D., Emery, P. R., Cai, Z., Ropchan, J., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05149-3 · Cited by 61 · see citing works
Bahri, M. A., Plenevaux, A., Aerts, J., Bastin, C., Becker, G., Mercier, J., Valade, A., Buchanan, T., Mestdagh, N., Ledoux, D., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.004 · Cited by 61 · see citing works
Cai, H., Mangner, T. J., Muzik, O., Wang, M.-W., Chugani, D. C., & Chugani, H. T. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500285t · Cited by 58 · see citing works
Warnier, C., Lemaire, C., Becker, G., Zaragoza, G., Giacomelli, F., Aerts, J., Otabashi, M., Bahri, M. A., Mercier, J., Plenevaux, A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00905 · Cited by 58 · see citing works
Validation and noninvasive kinetic modeling of [ <sup>11</sup> C]UCB-J PET imaging in mice
Bertoglio, D., Verhaeghe, J., Miranda, A., Kertesz, I., Cybulska, K., Korat, Š., Wyffels, L., Stroobants, S., Mrzljak, L., Dominguez, C., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19864081 · Cited by 54 · see citing works
Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H
Bretin, F., Warnock, G., Bahri, M. A., Aerts, J., Mestdagh, N., Buchanan, T., Valade, A., Mievis, F., Giacomelli, F., Lemaire, C., et al. (2013) · EJNMMI Research · doi:10.1186/2191-219x-3-35 · Cited by 43 · see citing works
Silencing of amygdala circuits during sepsis prevents the development of anxiety-related behaviours
Bourhy, L., Mazeraud, A., Costa, L. H. A., Levy, J., Rei, D., Hecquet, E., Gabanyi, I., Bozza, F. A., Chrétien, F., Lledo, P.-M., et al. (2022) · Brain · doi:10.1093/brain/awab475 · Cited by 37 · see citing works
Wu, P.-P., Cao, B.-R., Tian, F.-Y., & Gao, Z.-B. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-023-01138-2 · Cited by 35 · see citing works
Pharmacokinetic Characterization of [<sup>18</sup>F]UCB-H PET Radiopharmaceutical in the Rat Brain
Becker, G., Warnier, C., Serrano, M. E., Bahri, M. A., Mercier, J., Lemaire, C., Salmon, E., Luxen, A., & Plenevaux, A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00235 · Cited by 31 · see citing works
Quantification of SV2A Binding in Rodent Brain Using [18F]SynVesT-1 and PET Imaging
Sadasivam, P., Fang, X. T., Toyonaga, T., Lee, S., Xu, Y., Zheng, M.-Q., Spurrier, J., Huang, Y., Strittmatter, S. M., Carson, R. E., et al. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01567-9 · Cited by 31 · see citing works
Synaptic changes in psychiatric and neurological disorders: State-of-the art of in vivo imaging
Howes, O., Marcinkowska, J., Turkheimer, F. E., & Carr, R. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01943-x · Cited by 34 · see citing works
Bertoglio, D., Zajicek, F., Lombaerde, S. D., Miranda, A., Stroobants, S., Wang, Y., Dominguez, C., Munoz-Sanjuan, I., Bard, J., Liu, L., et al. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x221101648 · Cited by 29 · see citing works
Visser, M., O’Brien, J. T., & Mak, E. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102197 · Cited by 28 · see citing works
Fronczak, K. M., Li, Y., Henchir, J., Dixon, C. E., & Carlson, S. W. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02534-3 · Cited by 18 · see citing works
Interaction of Approved Drugs with Synaptic Vesicle Protein 2A
Danish, A., Namasivayam, V., Schiedel, A. C., & Müller, C. E. (2017) · Archiv der Pharmazie · doi:10.1002/ardp.201700003 · Cited by 19 · see citing works
Analysis of Differential Expression of Synaptic Vesicle Protein 2A in the Adult Rat Brain
Mendoza-Torreblanca, J. G., García-Cruz, M. E., Sánchez-Cruz, I., Gomez-Gonzalez, B., Juárez-Méndez, S., & Gómez-Lira, G. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.09.004 · Cited by 18 · see citing works
Bradberry, M. M., & Chapman, E. R. (2022) · The Journal of Physiology · doi:10.1113/jp282601 · Cited by 16 · see citing works
Presynaptic antiseizure medications-basic mechanisms and clues for their rational combinations
Czapińska-Ciepiela, E. K., Łuszczki, J., Czapiński, P., Czuczwar, S. J., & Lasoń, W. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00603-7 · Cited by 13 · see citing works
Small, C., Harper, C., Jiang, A., Kontaxi, C., Pronot, M., Yak, N., Malapaka, A., Davenport, E. C., Wallis, T. P., Gormal, R. S., et al. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16186 · Cited by 14 · see citing works
Asch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13 · see citing works
Hogg, J. A., & Cousin, M. A. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.16308 · Cited by 5 · see citing works
- Authors
- Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B.
- Affiliations
- University of Washington (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-06-21
- Volume
- 101
- Issue
- 26
- Pages
- 9861-9866
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC470764
- OpenAlex
- W2127801604
- Cited by
- 1,610
- References
- 30
- Citations by year
- 2026: 46 · 2025: 71 · 2024: 55 · 2023: 52 · 2022: 70 · 2021: 76 · 2020: 243 · 2019: 64 · 2018: 52 · 2017: 76 · 2016: 70 · 2015: 72 · 2014: 62 · 2013: 63 · 2012: 58
- FWCI
- 38.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (R01MH059842, R01 MH59842)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- SV2A, levetiracetam, synaptic vesicles, drug binding sites, antiepileptic drugs, SV2B, SV2C, audiogenic seizures, epilepsy, photoaffinity labeling, vesicle exocytosis, drug target identification, seizure protection
- MeSH terms
- Levetiracetam, Animals, Anticonvulsants, Binding Sites, Brain, Fibroblasts, Humans, Intracellular Membranes, Membrane Glycoproteins, Molecular Weight, Nerve Tissue Proteins, Piracetam, Precipitin Tests, Protein Binding, Seizures, Synaptic Vesicles, Gene Deletion, Mice, Knockout, Photoaffinity Labels, Inhibitory Concentration 50, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
